Drug intelligence / Profile preview

CLX-EX

Development stage: Preclinical
Lead developer: Cytosinlab Pharmaceutical Technology
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

CLX-EX is an experimental DNA-modulating agent being developed by CytosinLab for the treatment of gastrointestinal cancer. As part of CytosinLab's focus on epigenetic therapies, CLX-EX is designed to interact with and modulate DNA to exert antineoplastic effects. While the specific molecular target and detailed mechanism of action remain undisclosed, the drug is positioned within the company's pipeline alongside other epigenetic modulators such as PRMT1 and PRMT5 inhibitors. It is currently in the early stages of development, specifically targeting malignancies within the digestive tract.

Targets

DNA

Beyond the preview

Go deeper on CLX-EX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLX-EX.

Explore the full profile